RU2011152514A - Композиция для лечения доброкачественной гиперплазии простаты - Google Patents
Композиция для лечения доброкачественной гиперплазии простаты Download PDFInfo
- Publication number
- RU2011152514A RU2011152514A RU2011152514/15A RU2011152514A RU2011152514A RU 2011152514 A RU2011152514 A RU 2011152514A RU 2011152514/15 A RU2011152514/15 A RU 2011152514/15A RU 2011152514 A RU2011152514 A RU 2011152514A RU 2011152514 A RU2011152514 A RU 2011152514A
- Authority
- RU
- Russia
- Prior art keywords
- degarelix
- solvent
- salt
- pharmaceutically acceptable
- concentration
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 10
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 title claims abstract 5
- 208000004403 Prostatic Hyperplasia Diseases 0.000 title claims abstract 5
- 108010052004 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide Proteins 0.000 claims abstract 32
- MEUCPCLKGZSHTA-XYAYPHGZSA-N degarelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CC=1C=CC(NC(=O)[C@H]2NC(=O)NC(=O)C2)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(NC(N)=O)C=C1 MEUCPCLKGZSHTA-XYAYPHGZSA-N 0.000 claims abstract 32
- 229960002272 degarelix Drugs 0.000 claims abstract 32
- 150000003839 salts Chemical class 0.000 claims abstract 32
- 239000002904 solvent Substances 0.000 claims abstract 26
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 13
- 229940079593 drug Drugs 0.000 claims abstract 8
- 239000003814 drug Substances 0.000 claims abstract 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract 2
- 229930195725 Mannitol Natural products 0.000 claims abstract 2
- 235000010355 mannitol Nutrition 0.000 claims abstract 2
- 239000000594 mannitol Substances 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Detergent Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09251738 | 2009-07-06 | ||
| EP09251738.2 | 2009-07-06 | ||
| US23581609P | 2009-08-21 | 2009-08-21 | |
| US61/235,816 | 2009-08-21 | ||
| PCT/IB2010/001785 WO2011004260A2 (en) | 2009-07-06 | 2010-07-05 | Composition for the treatment of benign prostate hyperplasia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011152514A true RU2011152514A (ru) | 2013-08-20 |
Family
ID=41112615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011152514/15A RU2011152514A (ru) | 2009-07-06 | 2010-07-05 | Композиция для лечения доброкачественной гиперплазии простаты |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20110039787A1 (enExample) |
| EP (1) | EP2451469B1 (enExample) |
| JP (1) | JP2012532188A (enExample) |
| KR (1) | KR20120038956A (enExample) |
| CN (1) | CN102470159A (enExample) |
| AR (1) | AR081439A1 (enExample) |
| AU (1) | AU2010269958A1 (enExample) |
| BR (1) | BR112012000185A2 (enExample) |
| CA (1) | CA2766008A1 (enExample) |
| IL (1) | IL216987A0 (enExample) |
| MX (1) | MX2012000315A (enExample) |
| NZ (1) | NZ597060A (enExample) |
| RU (1) | RU2011152514A (enExample) |
| SA (1) | SA110310575B1 (enExample) |
| TW (1) | TW201105344A (enExample) |
| UY (1) | UY32769A (enExample) |
| WO (1) | WO2011004260A2 (enExample) |
| ZA (1) | ZA201109513B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0117057D0 (en) * | 2001-07-12 | 2001-09-05 | Ferring Bv | Pharmaceutical composition |
| JOP20090061B1 (ar) | 2008-02-11 | 2021-08-17 | Ferring Int Center Sa | طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH |
| WO2010125468A1 (en) * | 2009-05-01 | 2010-11-04 | Ferring International Center Sa | Composition for the treatment of prostate cancer |
| US20110039787A1 (en) * | 2009-07-06 | 2011-02-17 | Ferring International Center S.A. | Compositions, kits and methods for treating benign prostate hyperplasia |
| EP2447276A1 (en) | 2010-10-27 | 2012-05-02 | Ferring B.V. | Process for the manufacture of Degarelix and its intermediates |
| PL2632934T3 (pl) | 2010-10-27 | 2017-06-30 | Ferring B.V. | Sposób wytwarzania degareliksu i jego związków pośrednich |
| JO3755B1 (ar) | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
| WO2013104745A1 (en) * | 2012-01-13 | 2013-07-18 | Ferring Bv | Pharmaceutical composition |
| WO2013178788A2 (en) | 2012-06-01 | 2013-12-05 | Ferring B.V. | Manufacture of degarelix |
| HUP1400294A2 (hu) | 2014-06-13 | 2015-12-28 | Skillpharm Kft | Clopidogrel új alkalmazása |
| US12274680B2 (en) | 2022-09-13 | 2025-04-15 | II George William Creasy | Treatment of benign prostatic hypertrophy with capsinoids |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| JP2719233B2 (ja) * | 1991-04-25 | 1998-02-25 | デゲンギ，ロマノ | 黄体形成ホルモン放出ホルモン拮抗ペプチド |
| SI9300468A (en) * | 1992-10-14 | 1994-06-30 | Hoffmann La Roche | Injectable composition for the sustained release of biologically active compounds |
| US5506207A (en) * | 1994-03-18 | 1996-04-09 | The Salk Institute For Biological Studies | GNRH antagonists XIII |
| US5595760A (en) * | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
| US5860957A (en) * | 1997-02-07 | 1999-01-19 | Sarcos, Inc. | Multipathway electronically-controlled drug delivery system |
| US5821230A (en) * | 1997-04-11 | 1998-10-13 | Ferring Bv | GnRH antagonist decapeptides |
| US5925730A (en) * | 1997-04-11 | 1999-07-20 | Ferring Bv | GnRH antagonists |
| FR2776520B1 (fr) * | 1998-03-25 | 2000-05-05 | Sod Conseils Rech Applic | Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation |
| GB0117057D0 (en) * | 2001-07-12 | 2001-09-05 | Ferring Bv | Pharmaceutical composition |
| AR042815A1 (es) * | 2002-12-26 | 2005-07-06 | Alza Corp | Dispositivo de suministro de agente activo que tiene miembros compuestos |
| EP1674082A1 (de) * | 2004-12-22 | 2006-06-28 | Zentaris GmbH | Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel |
| GB0506759D0 (en) * | 2005-04-02 | 2005-05-11 | Medical Res Council | Combination treatment methods |
| EP1891964A1 (en) * | 2006-08-08 | 2008-02-27 | AEterna Zentaris GmbH | Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits |
| EP1967202A1 (en) * | 2007-03-05 | 2008-09-10 | AEterna Zentaris GmbH | Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity |
| JOP20090061B1 (ar) * | 2008-02-11 | 2021-08-17 | Ferring Int Center Sa | طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH |
| EP2257324B1 (en) * | 2008-02-11 | 2016-07-27 | Safety Syringes, Inc. | Syringe with safety needle guard and clip to prevent release of guard during reconstitution process |
| WO2010125468A1 (en) * | 2009-05-01 | 2010-11-04 | Ferring International Center Sa | Composition for the treatment of prostate cancer |
| TW201043221A (en) * | 2009-05-06 | 2010-12-16 | Ferring Int Ct Sa | Kit and method for preparation of a Degarelix solution |
| US20110039787A1 (en) * | 2009-07-06 | 2011-02-17 | Ferring International Center S.A. | Compositions, kits and methods for treating benign prostate hyperplasia |
| PL2632934T3 (pl) * | 2010-10-27 | 2017-06-30 | Ferring B.V. | Sposób wytwarzania degareliksu i jego związków pośrednich |
| EP2447276A1 (en) * | 2010-10-27 | 2012-05-02 | Ferring B.V. | Process for the manufacture of Degarelix and its intermediates |
| JO3755B1 (ar) * | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
| ES2655172T3 (es) * | 2011-07-15 | 2018-02-19 | Ferring B.V. | Procedimiento para preparación temporal de una colonoscopia en la que se administra una composición de picosulfato |
-
2010
- 2010-07-02 US US12/829,467 patent/US20110039787A1/en not_active Abandoned
- 2010-07-05 TW TW099122050A patent/TW201105344A/zh unknown
- 2010-07-05 MX MX2012000315A patent/MX2012000315A/es active IP Right Grant
- 2010-07-05 RU RU2011152514/15A patent/RU2011152514A/ru unknown
- 2010-07-05 WO PCT/IB2010/001785 patent/WO2011004260A2/en not_active Ceased
- 2010-07-05 CA CA2766008A patent/CA2766008A1/en not_active Abandoned
- 2010-07-05 CN CN2010800295366A patent/CN102470159A/zh active Pending
- 2010-07-05 NZ NZ597060A patent/NZ597060A/xx not_active IP Right Cessation
- 2010-07-05 AU AU2010269958A patent/AU2010269958A1/en not_active Abandoned
- 2010-07-05 JP JP2012519078A patent/JP2012532188A/ja active Pending
- 2010-07-05 BR BR112012000185A patent/BR112012000185A2/pt not_active IP Right Cessation
- 2010-07-05 US US13/381,762 patent/US20120172302A1/en not_active Abandoned
- 2010-07-05 KR KR1020127000337A patent/KR20120038956A/ko not_active Withdrawn
- 2010-07-05 EP EP10740272.9A patent/EP2451469B1/en not_active Not-in-force
- 2010-07-06 SA SA110310575A patent/SA110310575B1/ar unknown
- 2010-07-06 AR ARP100102410A patent/AR081439A1/es unknown
- 2010-07-07 UY UY0001032769A patent/UY32769A/es not_active Application Discontinuation
-
2011
- 2011-12-15 IL IL216987A patent/IL216987A0/en unknown
- 2011-12-22 ZA ZA2011/09513A patent/ZA201109513B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL216987A0 (en) | 2012-02-29 |
| KR20120038956A (ko) | 2012-04-24 |
| AR081439A1 (es) | 2012-09-05 |
| US20110039787A1 (en) | 2011-02-17 |
| AU2010269958A1 (en) | 2012-01-19 |
| JP2012532188A (ja) | 2012-12-13 |
| TW201105344A (en) | 2011-02-16 |
| US20120172302A1 (en) | 2012-07-05 |
| SA110310575B1 (ar) | 2014-10-23 |
| CN102470159A (zh) | 2012-05-23 |
| MX2012000315A (es) | 2012-02-13 |
| UY32769A (es) | 2011-02-28 |
| CA2766008A1 (en) | 2011-01-13 |
| BR112012000185A2 (pt) | 2017-06-13 |
| WO2011004260A2 (en) | 2011-01-13 |
| WO2011004260A3 (en) | 2011-05-19 |
| ZA201109513B (en) | 2012-09-26 |
| NZ597060A (en) | 2013-05-31 |
| EP2451469B1 (en) | 2014-08-20 |
| EP2451469A2 (en) | 2012-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011152514A (ru) | Композиция для лечения доброкачественной гиперплазии простаты | |
| RU2011142843A (ru) | Композиция для лечения рака предстательной железы | |
| ATE470443T1 (de) | Indol-1-yl-essigsäurederivate | |
| JP2012532188A5 (enExample) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| CY1111159T1 (el) | Πυκνα διαλυματα μεθοτρεξατης | |
| CO6160321A2 (es) | Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo | |
| EA201590835A1 (ru) | Составы с низкой дозой панкрелипазы и кишечнорастворимым покрытием | |
| EA200601747A1 (ru) | Три(цикло)замещённые амидные соединения | |
| EA201171429A1 (ru) | Противораковое соединение и содержащая его фармацевтическая композиция | |
| EA201190161A1 (ru) | Способ получения твердых лекарственных форм солифенацина и его фармацевтически приемлемых солей для перорального введения | |
| RU2011136636A (ru) | Фармацевтическая композиция для орального введения | |
| WO2010005980A8 (en) | Tacrolimus for improved treatment of transplant patients | |
| RU2015102772A (ru) | Бензодиазелипы для мелкоклеточного рака легкого | |
| EA200601901A1 (ru) | Композиции, содержащие иммуномодулирующие соединения для лечения и управления течением миелодиспластических синдромов и способы с их использованием | |
| NZ591408A (en) | Paracetamol and Calcium carbonate composition | |
| EA200700976A1 (ru) | Соединения в виде молекул-конъюгатов, обладающих повышенной активностью в отношении включения клеткой | |
| NO20064811L (no) | 4-(5-aminometyl-2-fluor-fenyl)-piperidin-1-yl]-(4-brom-3-metyl-5-propoksy-tiofen-2-yl)-metanonhydroklorid som en inhibitor av mastcelletryptase | |
| EA201070315A1 (ru) | Жидкая лекарственная форма конъюгата | |
| RU2008146217A (ru) | Фармацевтическая композиция, содержащая производное таксана, которая предназначена для приготовления инфузионного раствора, способ его приготовления и использование | |
| WO2007064448A3 (en) | Cancer treatment using fts and 2-deoxyglucose | |
| UA109544C2 (uk) | Фармацевтична композиція, що містить парацетамол, та спосіб її виготовлення | |
| RU2011131772A (ru) | Генерируемые в результате инсульта усилители ангиогенеза и их применение | |
| Mohammadi et al. | A comparison of the central versus peripheral gastrointestinal prokinetic activity of two novel ghrelin mimetics | |
| RU2007132971A (ru) | Способы и материалы с транс-кломифеном для лечения мужского бесплодия |